Ilmarinen Mutual Pension Insurance Co Has $60.80 Million Position in Johnson & Johnson $JNJ

Key Points

• Ilmarinen Mutual Pension Insurance Co has increased its position in Johnson & Johnson by 2.8%, owning 366,600 shares valued at approximately $60.8 million.
• Institutional investors and hedge funds now own 69.55% of Johnson & Johnson's stock, with notable acquisitions from firms like Nuveen LLC and GAMMA Investing LLC.
• Johnson & Johnson recently declared a quarterly dividend of $1.30 per share, representing a 2.9% yield with a payout ratio of 55.61%.

Ilmarinen Mutual Pension Insurance Co increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 366,600 shares of the company's stock after buying an additional 10,000 shares during the period. Johnson & Johnson accounts for 0.5% of Ilmarinen Mutual Pension Insurance Co's portfolio, making the stock its 23rd largest holding. Ilmarinen Mutual Pension Insurance Co's holdings in Johnson & Johnson were worth $60,797,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Nuveen LLC acquired a new stake in shares of Johnson & Johnson in the first quarter worth $1,369,188,000. GAMMA Investing LLC raised its holdings in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after buying an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares in the last quarter. Pacer Advisors Inc. grew its stake in Johnson & Johnson by 1,382.0% during the first quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after buying an additional 2,825,626 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $349,206,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on JNJ shares. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. Guggenheim reiterated a "neutral" rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Citigroup raised their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Finally, Morgan Stanley lifted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Stock Down 0.6%

Shares of Johnson & Johnson stock opened at $177.12 on Wednesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $426.57 billion, a P/E ratio of 18.94, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The business has a 50-day moving average of $169.51 and a two-hundred day moving average of $161.02.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the company posted $2.82 earnings per share. The company's quarterly revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's payout ratio is 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.